Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis: Results from a 1-Year, Multicentre, Open-Label, Single-Arm Study in a Clinical Setting Author Interview: Dr. Ronald B Vender, MD FRCPC Associate Clinical Professor at McMaster University in the Department of Medicine, Division of Dermatology DermatologistsBlog.com: What are the main findings of [...]
All posts in category Biologics
Psoriasis Patients on Etanercept: Work Productivity & Resource Outcomes at One Year
Posted by admin on August 14, 2012
http://dermatologistsblog.com/psoriasis/psoriasis-patients-on-etanercept-work-productivity-resource-outcomes-at-one-year/
Safety of ustekinumab (Stelara) in patients with moderate-to-severe psoriasis and latent tuberculosis infection
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection Author Interview: Dr. Tsai, Tsen-Fang Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan DermatologistsBlog.com What are the main findings of the study? This study evaluated the safety of isoniazid (INH) prophylaxis for newly identified latent tuberculosis infection (LTBI) in patients [...]
Posted by admin on July 20, 2012
http://dermatologistsblog.com/psoriasis/safety-of-ustekinumab-stelara-in-patients-with-moderate-to-severe-psoriasis-and-latent-tuberculosis-infection/
Vitamin D & ‘Alarmins’ in Psoriasis
Vitamin D Analog Calcipotriol Suppresses the Th17 Cytokine-Induced Proinflammatory S100 “Alarmins” Psoriasin (S100A7) and Koebnerisin (S100A15) in Psoriasis. Author Interview: Dr.med. Ronald Wolf Department of Dermatology and Allergology, Ludwig-Maximilian University, Munich, Germany What are the main findings of the study? Originally identified as antimicrobial peptides (AMP), we discover that Psoriasin (S100A7) and Koebnerisin (S100A15) also [...]
Posted by admin on April 18, 2012
http://dermatologistsblog.com/psoriasis/vitamin-d-alarmins-in-psoriasis/
Brodalumab for Psoriasis : Dr. Papp
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis Author Interview: Kim A. Papp, MD, PhD, FRCPC Probity Medical Research 30 Union Street East Waterloo ON N2J 1B7 What are the main findings of the study? From a purely technical aspect, the study achieved its primary endpoint with statistically significant mean percentage improvements in PASI score higher in all [...]
Posted by admin on March 29, 2012
http://dermatologistsblog.com/psoriasis/broadalumab_dr_papp/
Categories
Dermatology Author Interviews
Twitter
-
-
National Eczema Association
National Eczema Association
Pages
-
Dermatology Research Studies from NIH
Dermatology Meetings & Skin Care Events
June 2013 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 -
